Genetic changes in ALK-positive lung cancer over time
Part of Cancer, Lungs & breathing clinical trials.
This study looks at the genetic changes in ALK-positive lung cancer over time. It is for people who have already started one of three targeted treatments (alectinib, brigatinib, or lorlatinib) and are willing to provide extra tissue or blood samples for testing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced non-small cell lung cancer (NSCLC) with a change in the ALK gene (ALK-positive).
- You have already started treatment with a targeted drug called alectinib, brigatinib, or lorlatinib for at least 28 days.
- You are able to care for yourself (performance status 0, 1, or 2).
- You are 18 years or older and willing to sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial studies how alectinib (an ALK-blocking medicine) moves through the body and how it’s tolerated in people with advanced non-small cell lung cancer (NSCLC) that has an ALK rearrangement. You may be considered if you have ALK-positive, recurrent or advanced disease and have already had specific prior treatments.
This Phase 2 trial tests pembrolizumab (an immune therapy), bevacizumab (a medicine that blocks blood-vessel growth), and chemotherapy in people with ALK-rearranged lung cancer that is still present after the first treatment with alectinib. It aims to shrink tumors and improve control of the cancer.
This Phase 2 trial studies treatment strategies for people with stage IV non-small cell lung cancer (NSCLC) who have certain cancer gene mutations (like EGFR, ALK, or ROS1). It aims to see how different treatments affect survival and tumor response.
This trial looks at the “molecular landscape,” meaning the specific gene changes driving your lung cancer, for people whose non-small cell lung cancer (NSCLC) has rare mutations. The goal is to better understand what those rare changes mean and how they could guide treatment decisions.
This study looks at why some lung cancers with an ALK gene change do not respond to ALK-targeted drugs. It may help find better treatments for patients whose cancer stops responding early.
This study looks at biological changes in advanced lung cancer that has an ALK rearrangement, using regular blood samples (and sometimes tumor tissue if available). It may help researchers better understand how this cancer behaves and how it responds to first-line ALK-targeted treatment.
Hear when a new ALK Gene Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.